Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation.
Low dose of aripiprazole advanced sleep rhythm and reduced nocturnal sleep time in the patients with delayed sleep phase syndrome: an open-labeled clinical observation.
复制标题
DOI：
10.2147/ndt.s158865
复制
发表时间：
2018
影响因子：
3.2
通讯作者：
Shimizu T
中科院分区：
文献类型：
--
作者：
Omori Y;Kanbayashi T;Sagawa Y;Imanishi A;Tsutsui K;Takahashi Y;Takeshima M;Takaki M;Nishino S;Shimizu T
睡眠时相延迟综合征（DSPS）是一种慢性昼夜节律功能障碍，损害了受试者在社会、职业或其他领域的功能。在DSPS患者中发现抑郁症的发生率很高。阿立哌唑（APZ）是第二代抗精神病药，对抑郁症和精神分裂症均有效。近年来，APZ治疗DSPS和非24小时睡眠-觉醒节律紊乱的病例报道较少。因此，我们尝试使用APZ治疗DSPS伴抑郁症。纳入了12名受试者（包括4名女性），年龄为19-64岁。受试者最初接受0.5-3 mg APZ，每日一次，随后调整剂量。睡眠开始、睡眠中点和睡眠偏移分别显著提前1.1、1.8和2.5小时。出乎意料的是，治疗后睡眠时间明显缩短了1.3小时。他们的抑郁情绪表现出不明显的变化。低剂量APZ可使DSPS患者的睡眠节律提前，夜间睡眠时间减少。由于医生不容易治疗与DSPS相关的睡眠时间延长，这种药物将成为这些患者的新治疗选择。
Delayed sleep phase syndrome (DSPS) is a chronic dysfunction of circadian rhythm of the subject that impairs functioning in social, occupational, or other spheres. High rate of depression is found among DSPS patients. Aripiprazole (APZ), a second-generation antipsychotic, is effective in treatment of depression as well as schizophrenia. Recently, few case reports show the effectiveness of APZ in treating DSPS and non-24-hour sleep–wake rhythm disorder. Therefore, we tried to treat DSPS with depression using APZ. Twelve subjects (including four women) aged 19–64 years were included. The subjects were prescribed initially 0.5–3 mg of APZ once a day with subsequent dose adjustments. Sleep onset, midpoint of sleep, and sleep offset were significantly advanced by 1.1, 1.8, and 2.5 hours, respectively. Unexpectedly, sleep duration became significantly shorter by 1.3 hours after treatment. Their depressive moods showed an unremarkable change. Low dose of APZ advanced the sleep rhythm and reduced nocturnal sleep time in the subjects with DSPS. Since it is not easy for physicians to treat prolonged sleep duration often associated with DSPS, this medication would become a new therapeutic option for these patients.